Sign inJoin waitlistJoin the waitlist

Matthew Fury

Clinical Faculty · Louisiana State University School of Medicine

Credentials: · · · · ·

History

Louisiana State University School of Medicine
Present

Orthopaedic Sports Medicine
Hospital for Special Surgery
2022–2023
Orthopaedic Surgery
Harvard
2017–2022
Louisiana State University System
2013–2017
Economic and Educational Impact of Firearm-Related Injury on an Urban Trauma Center. Orthopedics.
2015–2016

Research

Assessment of Skeletal Maturity and Postoperative Growth Disturbance After Anterior Cruciate Ligament Reconstruction in Skeletally Immature Patients: A Systematic Review
Systematic review or meta-analysis · The American Journal of Sports Medicine · 2022 · First of 26 authors · 37 citations
Outpatient Shoulder Arthroplasty Patient Selection, Patient Experience, and Cost Analyses: A Systematic Review
Systematic review or meta-analysis · JBJS Reviews · 2021 · 24 citations
Return to Performance After Ulnar Collateral Ligament Reconstruction in Major League Baseball Pitchers: A Case-Control Assessment of Advanced Analytics, Velocity, Spin Rates, and…
Orthopaedic Journal of Sports Medicine · 2021 · First of 7 authors · Corresponding · 22 citations

Evan O’Donnell
5 papers · 2 as a fellow
Joshua Dines
5 papers
DB
David Bernstein
4 papers · 4 as a resident
Luke Oh
4 papers
Carl Cirino
3 papers · 1 as a fellow
Lawrence Gulotta
3 papers
Samuel Taylor
3 papers · 3 as a resident
Brian Forsythe
2 papers
Christopher Camp
2 papers
Elyse Berlinberg
2 papers
Eric Berkson
2 papers
JR
Julia Retzky
2 papers · 2 as a resident

Clinical trials

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2009–2013
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2009–2013
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2008–2013
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2007–2012